FINWIRES · TerminalLIVE
FINWIRES

TELUS啟動人工智慧加速器計劃，選擇Albion交付加值服務平台

By

-- TELUS（T.TO）週二宣布，已與L-SPARK合作推出一項計劃，旨在幫助具有高潛力的加拿大新創公司和成長型企業在加拿大最快、功能最強大的自主人工智慧超級電腦上建置、訓練和部署先進的人工智慧解決方案。 TELUS自主人工智慧加速器將使參與者能夠使用TELUS自主人工智慧工廠，並獲得L-SPARK提供的量身定制的商業諮詢支援。 TELUS表示，這項組合將幫助新創公司將雄心勃勃的人工智慧路線圖轉化為可擴展、市場就緒的產品，從而鞏固加拿大在全球人工智慧經濟中的地位。 參與公司包括Airy3D、Codalio、PataBid和TopoLift。 此外，TELUS也選擇Albion與Tecnotree合作，為其提供下一代加值服務（VAS）平台，並首先部署語音郵件應用程式。 根據合作協議，Albion 將利用 Tecnotree 成熟的加值服務和數位服務平台提供解決方案，以支援 TELUS 實現服務能力現代化的目標。 作為部署的一部分，Albion 將提供端到端的託管服務，包括平台營運、服務保障和持續的生命週期管理。

Price: $17.00, Change: $+0.42, Percent Change: +2.53%

Related Articles

Sectors

Sector Update: Tech Stocks Fall Late Afternoon

Tech stocks fell late Tuesday afternoon, with the State Street Technology Select Sector SPDR ETF (XLK) dropping 1.5% and the State Street SPDR S&P Semiconductor ETF (XSD) slumping 4.4%.The Philadelphia Semiconductor index shed 3.3%.In corporate news, OpenAI recently missed its own targets for new users and revenue, the Wall Street Journal reported late Monday, citing people familiar with the matter. Tech bellwether Nvidia (NVDA) fell 1.2%, Broadcom (AVGO) dropped 4.2%, Advanced Micro Devices (AMD) shed 3.1%, Oracle (ORCL) lost 3.6%, and Intel (INTC) declined 1.4%.Lam Research (LRCX), Applied Materials (AMAT) and KLA (KLAC) were among the chip equipment companies believed to have received a letter last week from the US Department of Commerce ordering them to halt certain tool shipments to China's second-largest chipmaker Hua Hong, Reuters reported. Lam declined 3%, Applied Materials dropped 5.1%, and KLA shed 4.1%.Amazon.com (AMZN) plans to make OpenAI's artificial intelligence models available to its customers after Microsoft (MSFT) relinquished its exclusive rights to resell the ChatGPT maker's products, Bloomberg reported Tuesday, citing Amazon Web Services CEO Matt Garman in a Bloomberg Television interview. Amazon shares were down 0.6%, and Microsoft rose 0.6%.Spotify Technology (SPOT) reported stronger-than-expected Q1 profit, but its premium subscriber growth and outlook disappointed investors. The stock fell 12%.

$AMAT$AMD$AMZN$AVGO$INTC$KLAC$LRCX$MSFT$NVDA$ORCL$SPOT
Research

Research Alert: Paccar: Q1 Eps Match Expectations; Class-8 Outlook Reiterated

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PCAR's Q1 results matched consensus with operating EPS of $1.15 vs. $0.96 in the prior year, supported by the absence of litigation charges that impacted Q1 2025. New truck deliveries fell 7K units to 33.1K globally, with North American Class-8 shipments declining while Europe showed strength. The Parts business managed positive expansion despite truck sales softness, benefiting from strategic investments in distribution infrastructure. Management maintained an upbeat tone on customer demand trends, though their North American outlook for retail Class-8 truck sales remained unchanged from Q4. PCAR generated healthy operating cash flow of $972M vs. $910M and maintained a strong balance sheet, in our view. Management projected full-year capex of ~$750M and R&D expenses of ~$475M for next-generation powertrains. We see the unchanged shipment projections as a signal that management is not entirely confident an inflection is occurring stronger than previously anticipated.

$PCAR
Australia

Erasca Shares Fall After Preliminary Phase 1 Dose Escalation Data

Erasca (ERAS) shares fell 48% Tuesday after the company reported preliminary phase 1 dose-escalation data for its experimental ERAS-0015 in patients with RAS-mutant solid tumors, including colorectal cancer, non-small-cell lung cancer and pancreatic adenocarcinoma.The preliminary data, from ongoing trials in the US and China, suggest ERAS-0015 may be combined with standard-of-care doses of panitumumab, positioning it as a potential backbone therapy for future combination regimens, the company said.The therapy was generally "well tolerated," with no dose-limiting toxicities or treatment discontinuations due to adverse events, according to a statement.Erasca said it selected 24 mg and 32 mg once daily as recommended doses for further study and said the drug showed "promising clinical potential" for combination use with panitumumab.In a regulatory filing, the company said a patient, who was a 66 year-old male with heavily pretreated metastatic pancreatic adenocarcinoma, had died. The company said grade 3 treatment-related adverse events of pneumonitis progressed to grade 5 following withdrawal of supportive care per patient decision.Price: $9.96, Change: $-9.20, Percent Change: -48.02%

$ERAS